This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: St Phi Therapeutics Co., Ltd.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Innovations by Steven Lingfeng Liu
Introduction
Steven Lingfeng Liu is an accomplished inventor based in Seattle, WA (US). He has made significant contributions to the field of immunology through his innovative work on chimeric endocytic receptors. His research focuses on enhancing immune responses, which has important implications for treating various diseases.
Latest Patents
Steven Liu holds a patent for "Chimeric endocytic receptors and method of use thereof." This invention discloses chimeric endocytic receptor (CER)-based constructs designed to activate and regulate immune responses. The constructs are based on the structure of FcγRI/γ chain and incorporate high-affinity binding domains from receptors or antibodies that can uptake specific antigens. This process allows for the presentation of antigens to T cells or B cells, initiating antigen-specific immune responses. The engineered CER-expressing monocytes (CER-M) or T cells (CER-T) can be utilized to treat tumors, viral diseases, and autoimmune diseases directly. The endocytosis process involving FcR-γ may enhance T cell activation, especially when combined with other constructs like CAR.
Career Highlights
Steven Liu is currently associated with St Phi Therapeutics Co., Ltd., where he continues to advance his research in immunotherapy. His work has positioned him as a key figure in the development of innovative therapeutic strategies aimed at improving immune system functionality.
Collaborations
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile